Who are Baxter International's decision-makers?
Baxter International is led by Andrew Hider. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Andrew Hider
- CFO/key exec
- Joel Grade
- Founded
- 1931
- Employees
- 37,500+
- HQ
- Deerfield, IL
- Status
- NYSE: BAX
- Andrew HiderPresident and Chief Executive OfficerCEO since 2025Leads Baxter's post-Kidney Care operating-model reset.
- Joel GradeExecutive Vice President and Chief Financial OfficerCFO since 2023Oversees finance and transformation planning.
- Heather KnightExecutive Vice President and Chief Operating OfficerCOO in 2026Runs operations and supply execution.
- Wil BorenSenior Vice President and President, Advanced SurgeryBusiness-unit leaderLeads a major product franchise.
Who leads Baxter International?
Baxter International's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Baxter International?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Baxter International organized as it scales?
Baxter International operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Baxter International leadershipBaxter International annual reports
Baxter International — frequently asked questions
